Stock CLNN CLENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
0.3718 USD +5.93% Intraday chart for Clene Inc. +13.01% +25.35%
May. 30 Clene Inc. Ratifies the Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for Fiscal Year 2024 CI
May. 08 Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clene to Present at the Emerging Growth Conference
AQ
Clene Inc. Ratifies the Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for Fiscal Year 2024
CI
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
AQ
Clene to Present at Upcoming May Conferences
AQ
Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M
MT
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
AQ
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
AQ
Clene : 2023 Annual Report to Stockholders
PU
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
AQ
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver
CI
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
AQ
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
AQ
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8
CI
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
AQ
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Clene to Present at the 36th Annual ROTH Conference
AQ
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
AQ
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLNN Stock
  4. News Clene Inc.